Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Concern about glucocorticoid-induced osteoporosis is warranted in all patients who take glucocorticoids for longer than 3 months, in any dosage. Bone mineral density should be measured and additional risk factors sought in order to determine whether bisphosphonate therapy is appropriate. Bisphosphonate therapy should be considered in postmenopausal women and in patients whose bone densitometry T-score is less than -1.5.
Orcel
Philippe
P
Fédération de rhumatologie, centre Viggo-Petersen, hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France. philippe.orcel@lrb.aphp.fr
D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy*; D000068296:Risedronic Acid; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate